Stanford University
Showing 1,301-1,310 of 1,329 Results
-
Wendy Sue Lewis Swanson
Adjunct Professor, Sean N. Parker Center for Allergy and Asthma Research - Lab
BioDr. Wendy Sue Swanson is a pediatrician, health communicator, and expert in digital health. She has dedicated her career to expanding the practice of general pediatrics in part by using public communication tools and digital software to improve education, connection between patients and care teams, and public health. Dr. Swanson started the first physician-authored blog for a major US hospital in 2009 working to combat misinformation in the news and online for families. She was a pioneer in using social media in medicine with a focus on increasing trust in the science and safety of immunizations. For more than a decade, she generated worldwide interest in pediatric public health topics, her team's digital health innovation projects, and prevention solutions by leveraging her blog, social channels, and media opportunities.
As Chief Medical Officer for a start-up, Dr. Swanson currently leads efforts to foster conversations around the importance of early and consistent inclusion of common allergens in babies' diets. In 2020 she designed an end-to-end, virtual clinical trial enrolling 1500 infants across the US focused on early infant feeding, leveraging EMR-based electronic and online parent chat rooms for novel participant recruitment.
As a pediatrician, author, and a prominent advocate of evidence-based medicine and prevention, Dr. Swanson speaks internationally on prevention, digital health, and health innovation. She has been a leading voice in health care and media, working to revolutionize health communications by using social and digital media to bridge the gap between parents and doctors.
Prior to her work at Stanford, Dr Swanson practiced primary care pediatrics for 12 years, worked for the NBC Seattle-affiliate, KING5 News, as a weekly on-air TV medical contributor, and wrote the Seattle Mama Doc blog for Seattle Children’s Hospital for 10 years. Swanson established and founded the Digital Health department in 2013 for the hospital and was later named Chief of Digital Innovation. In that role, Swanson led a team in innovation by testing and creating new digital tools (software, voice technology, social media, outside innovation pilots) and innovation projects across Seattle Children's and the US.
She is an official spokesperson for The American Academy of Pediatrics and a frequent contributor to national TV, radio, and online news outlets. Her first book, Mama Doc Medicine: Finding Calm and Confidence in Parenting, Child Health, and Work-Life Balance was published by the American Academy of Pediatrics in March, 2014 and is a Gold Award Recipient of the Mom’s Choice Awards.
Swanson was born and raised in Minnesota. An honors graduate in Psychology from Kenyon College, Dr. Swanson earned an MD and MBE (Master's in Bioethics) at the University of Pennsylvania Perelman School Of Medicine and completed her residency at Seattle Children’s Hospital. Dr. Swanson spent 2 years teaching middle school, bilingual, science & math in Oakland, California through Teach For America before beginning her career in medicine.
Career Focus: building solutions in prevention, health translation/education, and innovation via the design and development of novel and digital tools that 1) empower patients 2) help healthcare providers perform their jobs at the highest level 3) strengthen communication between these two groups and 4) prevent disease. -
James Swartz
James H. Clark Professor in the School of Engineering and Professor of Chemical Engineering and of Bioengineering
Current Research and Scholarly InterestsProgram Overview
The world we enjoy, including the oxygen we breathe, has been beneficially created by biological systems. Consequently, we believe that innovative biotechnologies can also serve to help correct a natural world that non-natural technologies have pushed out of balance. We must work together to provide a sustainable world system capable of equitably improving the lives of over 10 billion people.
Toward that objective, our program focuses on human health as well as planet health. To address particularly difficult challenges, we seek to synergistically combine: 1) the design and evolution of complex protein-based nanoparticles and enzymatic systems with 2) innovative, uniquely capable cell-free production technologies.
To advance human health we focus on: a) achieving the 120 year-old dream of producing “magic bullets”; smart nanoparticles that deliver therapeutics or genetic therapies only to specific cells in our bodies; b) precisely designing and efficiently producing vaccines that mimic viruses to stimulate safe and protective immune responses; and c) providing a rapid point-of-care liquid biopsy that will count and harvest circulating tumor cells.
To address planet health we are pursuing biotechnologies to: a) inexpensively use atmospheric CO2 to produce commodity biochemicals as the basis for a new carbon negative chemical industry, and b) mitigate the intermittency challenges of photovoltaic and wind produced electricity by producing hydrogen either from biomass sugars or directly from sunlight.
More than 25 years ago, Professor Swartz began his pioneering work to develop cell-free biotechnologies. The new ability to precisely focus biological systems toward efficiently addressing new, “non-natural” objectives has proven tremendously useful as we seek to address the crucial and very difficult challenges listed above. Another critical feature of the program is the courage (or naivete) to approach important objectives that require the development and integration of several necessary-but- not-sufficient technology advances. -
Andrew Sweatt
Clinical Assistant Professor, Medicine - Pulmonary, Allergy & Critical Care Medicine
Current Research and Scholarly InterestsAiming to advance understanding and treatment of pulmonary arterial hypertension (PAH), Dr. Sweatt's research leverages high-throughput molecular profiling, deep clinical phenotypic data, and data science (machine learning and network-based analysis) to identify novel sub-phenotypes and therapeutically-relevant biomarkers in PAH.
